Tempus ECG-AF vs VX1
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is proactive risk stratification and early identification of new-onset atrial fibrillation in an elderly patient population. This tool is ideal for screening patients aged 65 or older without pre-existing AF, enabling earlier follow-up and potential intervention to manage future AF development.
View Tempus ECG-AF →Choose VX1 if…
Choose Volta Medical's VX1 if you are a cardiac electrophysiologist performing atrial fibrillation or atrial tachycardia ablation procedures and require real-time AI assistance. This software is specifically designed to guide the identification of dispersed electrograms during an active ablation, aiming to enhance procedural precision and standardize outcomes.
View VX1 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | VX1 |
|---|---|---|
| Pricing | Contact vendor | Contact for pricing |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Software integrated with existing electrophysiology (EP) lab mapping and recording systems. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-AFTool A analyzes standard 12-lead ECGs, a routine and widely accessible diagnostic, making its integration into existing workflows and interpretation by a broader range of clinicians potentially simpler. Tool B, while integrated, operates in the highly specialized and real-time environment of an EP ablation lab, requiring specific expertise and procedural context.
Clinical Value
Tempus ECG-AFTool A provides predictive risk assessment for new-onset AF within 12 months, enabling earlier intervention and proactive management for a broad patient population. While Tool B significantly enhances a specialized ablation procedure, Tool A's potential for widespread early detection and prevention offers a broader clinical impact.
Pricing & Value
Tempus ECG-AFTool A explicitly details CMS reimbursement codes (CPT 0764T and CPT 0765T) and a Medicare rate of $128.90, providing clear financial transparency and a defined pathway for adoption and revenue generation for healthcare providers. Tool B's pricing information is less transparent, only stating 'contact for pricing' without public reimbursement details.
Enterprise Readiness
Tempus ECG-AFTool A explicitly confirms HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are fundamental requirements for data security and legal compliance in healthcare enterprises. Tool B's lack of explicit statements on these crucial aspects would necessitate additional due diligence for enterprise deployment.
Innovation
VX1Tool B offers real-time AI guidance during complex cardiac ablation procedures, directly assisting electrophysiologists in a dynamic, interventional setting to improve precision and standardize outcomes. While Tool A's predictive AI for AF risk from ECGs is innovative, Tool B's immediate, intra-procedural application represents a slightly more advanced and direct operational innovation in a specialized surgical context.
Support & Docs
Tempus ECG-AFTempus provides multiple avenues for support, including direct email ([email protected]), local representatives, and a comprehensive online 'Resource Center' with various content types, alongside explicit API documentation for integration. Volta Medical primarily highlights product-specific user manuals and Instructions For Use, which are essential but represent a narrower scope of support resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | VX1 |
|---|---|---|
| Name | Tempus ECG-AF | VX1 |
| Company | Tempus AI, Inc. | Volta Medical |
| Primary Function | Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. | Assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures. |
| Target Patient Population/Use Case | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, for earlier identification and follow-up of AF. | Cardiologists during AFib and atrial tachycardia ablation procedures. |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and VX1.